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ASSESSMENT OF THE EPILEPSY TREATMENT GAP
IN TWO CITIES OF SOUTH-EAST OF BRAZIL
Ana Lúcia Andrade Noronha, Lúcia Helena Marques, Moacir Alves Borges,
Fernando Cendes, Carlos Alberto Mantovani Guerreiro, Li Li Min
ABSTRACT - Objective: To assess the epilepsy treatment gap in Campinas and São José do Rio Preto, two
cities in the State of São Paulo, Brazil. Method: The treatment gap was estimated using the formula n1-
n2/n1x100, where n1 was calculated using 1.86% prevalence and represented the number of individuals
with epilepsy, while n2 represented the number of people who could be treated with an adult standard
dose for a year utilizing the antiepileptic drugs supplied by the public health system. Results: Our esti-
mates revealed that in 2001, approximately 50% of the population with epilepsy was treated with the rec-
ommended antiepileptic medication. Conclusion: These results suggest that a relevant percentage of patients
with epilepsy are not untreated. Further epidemiological studies are needed to investigate the reasons for
this treatment gap so that interventions can reduce this gap and improve the quality of life of patients
with epilepsy.
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A lacuna de tratamento em epilepsia em duas cidades do sudeste do Brasil
RESUMO - Objetivo: Estimar a lacuna de tratamento em epilepsia nas cidades de Campinas e São José do
Rio Preto, interior do Estado de São Paulo. Método: Estimamos a lacuna de tratamento através da fór-
mula n1-n2/n1x100, onde se utiliza o número de pessoas com epilepsia, calculado pela prevalência (n1), e
a quantidade de pessoas que podem ser tratadas com a dose padrão para adultos das DAEs, distribuídas
no período de um ano na localidade (n2). Usamos a prevalência estimada de 1,86% e consumo de medicação
antiepiléptica fornecida pela rede básica de saúde nestas duas cidades. Resultados: Nossas estimativas
mostram que somente em torno de metade da população com epilepsia foi tratada em 2001 usando do-
ses preconizadas de medicação antiepiléptica. Conclusão: A nossa estimativa aponta que uma parcela
importante dos pacientes com epilepsia não está sendo tratada no nosso meio. Estudos epidemiológicos
futuros devem explorar os motivos desta lacuna de tratamento para que intervenções sejam realizadas para
melhorar a qualidade de vida dos pacientes com epilepsia.
PALAVRAS-CHAVE: epilepsia, tratamento, lacuna de tratamento, drogas antiepilépticas, estigma.
Epilepsy is the most common serious neurologi-
cal disorder in the world. It has been estimated that
1% of the world population has some form of epi-
lepsy and the incidence is higher in developing co-
untries1. Borges demonstrated that the prevalen-
ce of epilepsy in Campinas and São José do Rio Pre-
to is 18.6 for every 1000 inhabitants2. This value
when extended to the entire country indicates
that there are more than three million individuals
with some form of epilepsy in Brazil. This high pre-
valence makes epilepsy a public health problem.
Without treatment, patients are unable to work
and/or require the constant supervision of a family
member, which means added social and econom-
ic burden for the family and state3. Moreover, an
untreated patient with epilepsy requires frequent
hospitalization due to the occurrence of seizures
or the traumas caused by the seizure or for reha-
bilitation. Thus, an untreated patient is a burden
to the State and to the family.
In addition to the socioeconomic factor, the pa-
tient is also affected by an affective-emotional fac-
tor because there is a social stigma attached to epi-
lepsy that is due lack of information about this con-
dition4. The patients are afraid of socially assum-
ing their epileptic condition fearing social discrim-
ination and stigmatization: they are unable to
find employment5,6; their personal relationships
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are not long lasting7,8 and they are excluded from
society. Therefore many patients do not accept
their diagnosis and attribute their seizures to super-
natural influences or religious problems8-10. They
treat them as such or do not undergo any treat-
ment, but keep their condition secret so that they
do not suffer discrimination10.
In developing countries, besides the socio-cultu-
ral problems, there are transport difficulties and ex-
treme poverty. Therefore, a patient who has to tra-
vel long distances to receive adequate treatment
does not adhere to treatment because it is trouble-
some and financially difficult. This aspect has been
observed by the World Health Organization (WHO)
and has been studied by a team that classifies dis-
eases and disabilities that lead to loss of producti-
vity. They concluded that epilepsy is responsible for
0.5% of the expenditure allotted for worldwide in-
capacitating diseases and proposed actions that
would reduce the incapability of patients with
epilepsy11.
Hence, epilepsy in Brazil and all other develop-
ing countries needs greater attention. This study
was conducted with this purpose in mind. We did
a simple analysis of one of the aspects of the epile-
psy treatment gap in Brazil, studying the antiepi-
leptic drugs (AEDs) consumption. The Brazilian pu-
blic health system distributes some AEDs with re-
gional differences. The AEDs - carbamazepine, phe-
nytoin and phenobarbital - are distributed in most
cities in the State of São Paulo. In some of them,
valproic acid is also distributed under a municipal
directive. Campinas and São José do Rio Preto (SJRP)
are two cities included in the National Demons-
tration Project on Epilepsy in Brazil12 and these four
drugs are distributed in these cities. These two ci-
ties were analyzed to check if the quantity distrib-
uted was sufficient for the estimated population
with epilepsy. 
Campinas has approximately one million inhabi-
tants and is considered an important industrial as
well as commercial center. It has several universi-
ties and an extensive public health network consis-
ting of health centers and secondary hospitals.
São José do Rio Preto has a population of approxi-
mately 340000 inhabitants and also has a teach-
ing hospital attached to the Medical School of São
José do Rio Preto as well as a well-structured pub-
lic health system.
Our objective was to assess the epilepsy treatment
gap in Campinas and São José do Rio Preto in 2001.
METHOD
The indirect method was used to measure the treat-
ment gap of epilepsy by studying the data related to an-
tiepileptic drug availability at the Municipal Health Se-
cretaries in Campinas and São José do Rio Preto during
the year 2001. This study received the approval of the
Research Ethics Commission, from Faculty of Medical
Sciences, UNICAMP.
The following therapeutic doses were defined: carba-
mazepine (CBZ) - 800 mg/day; phenytoin (PHT) - 300 mg/day;
phenobarbital (PB) - 100 mg/day; valproic acid (VA) - 750
mg/day.
The number of individuals using the AEDs was based
on the quantity consumed and the therapeutic dose. For
example, we calculated the number of individuals who
could be treated with a dose of 800 mg/day utilizing the
quantity of carbamazepine distributed to each city.
The population with epilepsy in Campinas (1.000.000
inhabitants) and São José do Rio Preto (340000 inhabi-
tants) was calculated assuming a prevalence of 1.86%2.
The treatment gap was obtained applying the formula
n1-n2/n1x100, where n1 is the number of individuals
with epilepsy calculated according to the prevalence and
n2 is the number of individuals with epilepsy that could
be treated with a standard adult dose of AEDs for a year
in that region13.
RESULTS 
We estimated an population with epilepsy of
18600 individuals in Campinas and 6324 in Sao
José do Rio Preto, but the number of individuals
Table. An estimate of the number of patients using AEDS during the year 2001.
City Total CBZ PHT PB VA
N patients N patients N patients N patients N patients
(%) (%) (%) (%) (%)
Campinas 8,182 3,809 1,024 1,856 1,493
(44)* (47) (12) (23) (18)
São José do Rio Preto 2,591 706 451 1331 103
(41)* (28) (17) (51) (4)
*percentage of population with epilepsy estimated in the city. CBZ, carbamazepine; PHT, phenytoinl; PB, phenobar-
bital; AV, valproic acid.
 
utilizing antiepileptic drugs during 2001 was 8182
in Campinas and 2591 in São José do Rio Preto.
The Table demonstrates the total number of pa-
tients treated with each of the AEDs during 2001.
A tendency to use carbamazepine was observed in
Campinas (47%), while in SJRP there was greater
tendency to use phenobarbital (51%). Another ob-
servation was that valproic acid was less used in
SJRP (4%) than in Campinas (18%). After calcula-
ting the estimated number of individuals with
epilepsy and the quantity of medication distributed
in each city, the treatment gap in Campinas was
found to be 56% and in SJRP it was 59%.
DISCUSSION
Epilepsy is a condition that involves high psy-
cho-socio-economic costs 3. This expenditure is lar-
gely due to the fact that the disorder is not treat-
ed. However, effective treatment for epilepsy does
exist, the only problem is that this treatment may
not be available for all individuals with epilepsy
as suggested  by an analysis of the data in Campinas
and São José do Rio Preto.
Epilepsy treatment in Campinas and São José
do Rio Preto differed in relation to the preference
shown for certain AEDs. The reason for this differ-
ence should be investigated as it may indicate if
the control of seizures in a population is better with
a certain drug, which drugs can be better utilized
and if differences in the population are responsi-
ble for the choice of the drug.
Our estimates show that only about half the po-
pulation with epilepsy was treated in 2001. A fact
that should be investigated to find out if this is due
to a lack of awareness or the stigma associated with
this disorder or if there are any other factors res-
ponsible for the alarming treatment gap in these
two cities. This result was definitely not due to the
lack of medication as the final balance of the phar-
macies was positive. However, in some cases the
distribution flow was not continuous.
Campinas and São José do Rio Preto are two bu-
siness centers in the region that have reasonable
living conditions, infrastructure and healthcare
systems. Therefore, poorer cities in Brazil with far
more precarious conditions should present more
critical figures.
The indirect measurement of the treatment
gap is an extremely simplistic method for affirm-
ing the existence of a treatment gap as it does not
take into account other variables such as the acqui-
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sition of AEDs from private pharmacies or data re-
garding patients who obtain good control with sub-
doses or those who need higher doses or use more
than one drug nor those who use antiepileptic me-
dication to treat other diseases such as carbamaze-
pine to treat chronic pain and mood disorders or
even the fact that the public health system covers
only 70% of the population in the two cities. No-
netheless, it is universally accepted13-15 as a method
for measuring the treatment gap and providing an
estimate of how much should be invested in epi-
demiological studies on epilepsy, its control and the
distribution of drugs.
Based on this panorama, epidemiological stud-
ies should be conducted to obtain more precise data
so that treatment and distribution of medication
is improved, expenses reduced and patients with
epilepsy have a better quality of life.
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